Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: A systematic review and meta-analysis
Open accessAbstract
OBJECTIVES: The purpose of this meta-analysis is to evaluate the efficacy and safety of TAS-102 in treating metastatic colorectal cancer (mCRC) using the most recent data available. METHODS: The literature on the efficacy and safety of TAS-102 versus placebo and/or best supportive care (BSC) in mCRC was obtained through a systematic search of PubMed, Embase, and Web of Science databases through January 2023. Identify the included literature and extract pertinent data, such as the overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), disease control rate (DCR), incidence of adverse events (AEs) and serious adverse events (SAEs). RESULTS: There were eight eligible articles that included 2903 patients (1964 TAS-102 versus 939 Placebo and/or BSC). In this meta-analysis, TAS-102 treatment resulted in longer OS, PFS, TTF, and higher DCR in patients with mCRC versus placebo and/or BSC. TAS-102 improved OS and PFS in subgroup analyses of mCRC patients with KRAS wild-type and KRAS mutant-type. In addition, TAS-102 did not increase the incidence of serious adverse events. CONCLUSION: TAS-102 can enhance the prognosis of mCRC patients whose standard therapy has failed, regardless of KRAS mutation status, and its safety is acceptable.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A meta-analysis showed TAS-102 demonstrated significant mOS benefits in both KRAS WT patients (HR 0.66, 95% CI 0.55-0.79) and KRAS mutant patients (HR 0.75, 95% CI 0.62-0.91).
“A comprehensive meta-analysis showed that TAS-102 demonstrated significant mOS benefits in both KRAS WT patients (HR: 0.66, 95% CI 0.55, 0.79) and KRAS mutant patients (HR: 0.75, 95% CI 0.62, 0.91) [45].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · see citing works
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · see citing works
(2014) · Medical Entomology and Zoology · Cited by 17,633 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874 · see citing works
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · see citing works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works
Luo, D., Wan, X., Liu, J., & Tong, T. (2018) · Statistical Methods in Medical Research · doi:10.1177/0962280216669183 · Cited by 4,066 · see citing works
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · see citing works
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796 · see citing works
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687 · see citing works
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431 · see citing works
de Haes, J., van Knippenberg, F. C. E., & Neijt, J. P. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.434 · Cited by 907 · see citing works
Metastatic colorectal cancer: mechanisms and emerging therapeutics
Shin, A. E., Giancotti, F. G., & Rustgi, A. K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.01.003 · Cited by 692 · see citing works
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J. M., & Cervantes, A. M. R. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 537 · see citing works
Immunotherapy in colorectal cancer: current achievements and future perspective
Fan, A., Wang, B., Wang, X., Nie, Y., Fan, D., Zhao, X., & Lu, Y. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64077 · Cited by 415 · see citing works
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355 · see citing works
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326 · see citing works
Xu, J., Kim, T. W., Shen, L., Sriuranpong, V., Pan, H., Xu, R., Guo, W., Han, S., Liu, T., Park, Y. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3245 · Cited by 266 · see citing works
Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H., & Fukushima, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.571 · Cited by 120 · see citing works
Systemic treatment for metastatic colorectal cancer
Leowattana, W., Leowattana, P., & Leowattana, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1569 · Cited by 111 · see citing works
Cutsem, E. V., Mayer, R. J., Laurent, S., Winkler, R. E., Grávalos, C., Benavides, M., Longo-Muñoz, F., Portales, F., Ciardiello, F., Siena, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.009 · Cited by 96 · see citing works
Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update
Boukouris, A. E., Theochari, M., Stefanou, D. T., Papalambros, A., Felekouras, E. S., Gogas, H. J., & Ziogas, D. C. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103663 · Cited by 71 · see citing works
Yoshino, T., Cleary, J. M., Cutsem, E. V., Mayer, R. J., Ohtsu, A., Shinozaki, E., Falcone, A., Yamazaki, K., Nishina, T., García‐Carbonero, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.005 · Cited by 65 · see citing works
Bachet, J., Wyrwicz, L. S., Price, T. J., Cremolini, C., Phelip, J., Portales, F., Özet, A., Çiçin, İ., Atlan, D., Becquart, M., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000698 · Cited by 45 · see citing works
Colorectal cancer management: strategies in drug delivery
Singh, P., Waghambare, P., Khan, T. A., & Omri, A. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2084531 · Cited by 36 · see citing works
Colwell, H. H., Mathias, S. D., Turner, M. P., Lu, J., Wright, N., Peeters, M., Cella, D. F., & Devercelli, G. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0034 · Cited by 27 · see citing works
Velden, D. L. V. D., Opdam, F. L., & Voest, E. E. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2783 · Cited by 22 · see citing works
Weiss, L., Karthaus, M., Riera‐Knorrenschild, J., Kretzschmar, A. K., Welslau, M., Vehling‐Kaiser, U., Pelz, H., Ettrich, T. J., Hess, J., Reisländer, T., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100391 · Cited by 17 · see citing works
Cheung, W. Y., Kavan, P., & Dolley, A. (2020) · Current Oncology · doi:10.3747/co.27.6533 · Cited by 15 · see citing works
Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
Chen, D., Wu, Y., Lin, H., Wang, Y., Li, L., & Zhang, T. (2018) · Cancer Management and Research · doi:10.2147/cmar.s174584 · Cited by 11 · see citing works
Pietrantonio, F., Fucà, G., Manca, P., Pagani, F., Raimondi, A., Prisciandaro, M., Randon, G., Corti, F., de Braud, F., Cremolini, C., et al. (2020) · Tumori Journal · doi:10.1177/0300891620960808 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tabernero, J., Taieb, J., Fakih, M., Prager, G. W., Van Cutsem, E., Ciardiello, F., Mayer, R. J., Amellal, N., Skanji, D., Calleja, E., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102945 · Cited by 18 · see citing works
Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025) · Medicina · doi:10.3390/medicina61071202 · Cited by 10 · see citing works
Hu, Y., Du, Y., Qiu, Z., Zhu, C., Wang, J., Liang, T., Liu, T., & Da, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399998 · Cited by 5 · see citing works
Silva, L. F. L., Saldanha, E. F., da Conceição, L. D., Martins, W. D. A., Gismondi, R. A., Filho, E. M. D. S., & Peixoto, R. D. (2024) · ecancermedicalscience · doi:10.3332/ecancer.2024.1728 · Cited by 3 · see citing works
Hubbard, J. M., Zemla, T., Zhu, M., Graham, R. P., Jin, Z., Mitchell, J. L., Novo, E., Végh, É., Lőrincz, O., Csiszovszki, Z., et al. (2025) · JCO oncology advances. · doi:10.1200/oa-25-00108
Chen, E. Y.-S., Nabavizadeh, N., Kendsersky, N. D., Lessenich, C., Herzig, D. O., Korngold, E. K., Goodyear, S. M., Kennecke, H. F., Kardosh, A., Tsikitis, V. L., et al. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.02.001
- Authors
- Huang, F., Yang, H., Bao, W., Bin, Y., Zhou, S., Wang, M., & Lv, X.
- Affiliations
- First Affiliated Hospital of GuangXi Medical University (CN)
- Corresponding author
- Lv, Xiaoping
- Venue
- Clinical and Translational Oncology
- Published
- 2023-07-07
- Volume
- 26
- Issue
- 2
- Pages
- 468-476
- ISSN
- 1699-048X (ISSN-L)
- 1699-3055
- OpenAlex
- W4383481127
- Cited by
- 6
- References
- 33
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3
- FWCI
- 0.19
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-08-03)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical & Translational Oncology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81860104)
- Natural Science Foundation of Guangxi Zhuang Autonomous Region (2017GXNSFAA198299)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- trifluridine/tipiracil, metastatic colorectal cancer, overall survival, progression-free survival, time to treatment failure, disease control rate, adverse events, KRAS mutation status, second-line therapy
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Drug Combinations, Humans, Pyrrolidines, Rectal Neoplasms, Thymine, Trifluridine, Uracil, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
